{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T05:58:42Z","timestamp":1759730322383,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,9,2]]},"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The psoriatic arthritis (PsA) Observational Study of Persistence of Treatment (PRO-SPIRIT) assesses effectiveness and persistence of real-world PsA treatments. Ixekizumab (IXE) is an interleukin (IL)-17A inhibitor (i) (IL-17Ai), approved for the treatment of adult PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The aim of this predefined interim analysis was to report baseline characteristics along with early (3-month) descriptive and comparative real-world effectiveness in patients with PsA prescribed with advanced treatment including IL-17Ai; IXE or secukinumab (SEC), IL-12\/23i, IL-23i, tumour necrosis factor (TNFi) or Janus kinase (JAKi).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>1192 patients across 6 countries were analysed. At baseline, patients receiving IXE had longer disease duration and higher previous biological\/targeted-synthetic disease-modifying antirheumatic drugs experience than patients starting TNFi and SEC 150, and less concomitant conventional-synthetic DMARD use than TNFi and JAKi. Comparative analyses at 3 months showed that: (a) versus TNFi, IXE exhibited similar improvement in clinical Disease Activity in PsA (cDAPSA) but significantly greater improvement in body surface area affected by psoriasis (BSA) and global assessments (physician GA, patient GA (PatGA)); (b) versus IL-12\/23i and IL-23i (pooled), IXE showed significantly greater improvement in cDAPSA and PatGA; (c) IXE was as fast as JAKi in improving joint disease activity. Ad hoc analysis indicated that more patients with active psoriasis (BSA \u22653%) achieved minimal disease activity with IXE than JAKi or IL-12\/23i. The responses to SEC varied by dosage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This study confirms the rapid 3-month effectiveness of IXE on joint disease activity\u2014as fast as TNFi and JAKi (cDAPSA), and exceeding IL-12\/23i and IL-23i\u2014along with clear benefits to skin.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004318","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T02:35:21Z","timestamp":1726886121000},"page":"e004318","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study"],"prefix":"10.1136","volume":"10","author":[{"given":"Lars Erik","family":"Kristensen","sequence":"first","affiliation":[{"name":"The Parker Institute, Bispebjerg Hospital, Kobenhavn, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khai Jing","family":"Ng","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Ngantcha","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7545-6385","authenticated-orcid":false,"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[{"name":"Montpellier School of Medicine, University of Montpellier, Montpellier, France"},{"name":"Centre Hospitalier Universitaire de Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio","family":"Lubrano","sequence":"additional","affiliation":[{"name":"Medicine and Health Sciences, University of Molise, Campobasso, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7531-4125","authenticated-orcid":false,"given":"William","family":"Tillett","sequence":"additional","affiliation":[{"name":"University of Bath, Bath, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[{"name":"Internal Medicine II, Rheumatology, Schlosspark-Klinik GmbH, Berlin, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, University Health Network; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c0ngels","family":"Martinez Ferrer","sequence":"additional","affiliation":[{"name":"Hospital Universitario Doctor Peset, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baojin","family":"Zhu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3107-6692","authenticated-orcid":false,"given":"Dominika","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Holzk\u00e4mper","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8970-4116","authenticated-orcid":false,"given":"Nicola","family":"Gullick","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK"},{"name":"Warwick Medical School, University of Warwick, Coventry, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andris","family":"Kronbergs","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"de la Torre","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis G","family":"McGonagle","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"2025090313070326000_10.3.e004318.1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.7861\/clinmedicine.17-1-65","article-title":"Psoriatic arthritis: state of the art review","volume":"17","author":"Coates","year":"2017","journal-title":"Clin Med (Lond)"},{"key":"2025090313070326000_10.3.e004318.2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531"},{"key":"2025090313070326000_10.3.e004318.3","unstructured":"Gossec L , Smolen J . n.d. EULAR recommendations for the management of psoriatic arthritis: 2023 update. [PowerPoint presentation]. European Alliance of Associations for Rheumatology (EULAR). Presented June 3, 2023."},{"key":"2025090313070326000_10.3.e004318.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00798-0"},{"key":"2025090313070326000_10.3.e004318.5","unstructured":"US FDA . TALTZ (ixekizumab) injection, for subcutaneous use: US prescribing information, 2022. Available: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125521s000lbl.pdf"},{"key":"2025090313070326000_10.3.e004318.6","unstructured":"Taltz: European public assessment report (EPAR) European Medicines Agency. 2023. Available: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/taltz"},{"key":"2025090313070326000_10.3.e004318.7","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/acr.23738","article-title":"Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313070326000_10.3.e004318.8","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090313070326000_10.3.e004318.9","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1093\/rheumatology\/kez684","article-title":"Ixekizumab treatment of biologic-na\u00efve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)","volume":"59","author":"Chandran","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313070326000_10.3.e004318.10","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40744-020-00261-0","article-title":"Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)","volume":"8","author":"Orbai","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090313070326000_10.3.e004318.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025090313070326000_10.3.e004318.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2025090313070326000_10.3.e004318.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.5338"},{"key":"2025090313070326000_10.3.e004318.14","doi-asserted-by":"crossref","first-page":"1759720X231189005","DOI":"10.1177\/1759720X231189005","article-title":"The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P2","volume":"15","author":"Deodhar","year":"2023","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2025090313070326000_10.3.e004318.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025090313070326000_10.3.e004318.16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"2025090313070326000_10.3.e004318.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022516"},{"key":"2025090313070326000_10.3.e004318.18","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1111\/ijd.15644","article-title":"Real-world experience versus clinical trials: pros and cons in psoriasis therapy evaluation","volume":"61","author":"Cinelli","year":"2022","journal-title":"Int J Dermatol"},{"key":"2025090313070326000_10.3.e004318.19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/rheumatology\/key004","article-title":"Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients","volume":"57","author":"Schoels","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313070326000_10.3.e004318.20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39335.541782.AD"},{"key":"2025090313070326000_10.3.e004318.21","doi-asserted-by":"crossref","unstructured":"Morel J , Lubrano E , Tillett W , et al . AB1115 STUDY design and full baseline sample characteristics of patients from the 24-month multinational prospective psoriatic arthritis observational study of persistence of treatment (pro-spirit). EULAR 2023 Eur Congr Rheumatol 31 May - 3 June Milan, Italy 2023;1786\u20137. doi:10.1136\/annrheumdis-2023-eular.447","DOI":"10.1136\/annrheumdis-2023-eular.447"},{"key":"2025090313070326000_10.3.e004318.22","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215960","article-title":"DAPSA versus cDAPSA: Do we need to use CRP?","volume":"79","author":"Gon\u00e7alves","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2025090313070326000_10.3.e004318.23","unstructured":"Little RJA , Rubin DB . Statistical analysis with missing data. New York: John Wiley & Sons, 1987."},{"key":"2025090313070326000_10.3.e004318.24","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/63.3.581"},{"key":"2025090313070326000_10.3.e004318.25","doi-asserted-by":"crossref","unstructured":"Rubin DB . Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons, 1987.","DOI":"10.1002\/9780470316696"},{"key":"2025090313070326000_10.3.e004318.26","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1093\/rheumatology\/keab905","article-title":"Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis","volume":"61","author":"Nash","year":"2022","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090313070326000_10.3.e004318.27","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40744-023-00584-8","article-title":"Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study","volume":"10","author":"Joven","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025090313070326000_10.3.e004318.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-215003"},{"key":"2025090313070326000_10.3.e004318.29","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18851"},{"key":"2025090313070326000_10.3.e004318.30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15666"},{"key":"2025090313070326000_10.3.e004318.31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","article-title":"Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis","volume":"34","author":"Egeberg","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090313070326000_10.3.e004318.32","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-022-00284-w","article-title":"Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study","volume":"6","author":"Colombo","year":"2022","journal-title":"BMC Rheumatol"},{"key":"2025090313070326000_10.3.e004318.33","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1093\/rheumatology\/keaa710","article-title":"Secukinumab and ustekinumab treatment in psoriatic arthritis: results of a direct comparison","volume":"60","author":"Letarouilly","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313070326000_10.3.e004318.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-023-03058-y","article-title":"Improvement in patient-reported outcomes and work productivity following 3-year ustekinumab or tumour necrosis factor inhibitor treatment in patients with psoriatic arthritis: results from the PsABio real-world study","volume":"25","author":"Gossec","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"2025090313070326000_10.3.e004318.35","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151979","article-title":"Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries","volume":"53","author":"Egeberg","year":"2022","journal-title":"Semin Arthritis Rheum"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:07:13Z","timestamp":1756930033000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,9,20]]},"published-print":{"date-parts":[[2024,9]]}},"alternative-id":["10.1136\/rmdopen-2024-004318"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004318","relation":{},"ISSN":["2056-5933"],"issn-type":[{"type":"electronic","value":"2056-5933"}],"subject":[],"published":{"date-parts":[[2024,9]]}}}